2026 Medical Fee Revision — Consultation Fees Effectively Raised
From June 2026, new price-adjustment surcharges effectively raise initial consultation by ~¥20 and follow-up by ~¥30. Affects out-of-pocket costs for foreign residents at 30% copay.
Effective Aug 2026; monthly cap up 4–38% + new annual cap of ¥530,000
The High-Cost Medical Expenses Benefit refunds medical costs that exceed a set monthly limit. In the first-phase revision on August 1, 2026, monthly out-of-pocket caps are raised by 4–38% across income brackets, and a new annual cap of ¥530,000 is introduced for those with ¥2–7.7M annual income.
| Before | After | Δ | |
|---|---|---|---|
| ~¥11.6M annual | ¥252,600+α | ¥348,000+α | +38% |
| ¥7.7M~¥11.6M | ¥167,400+α | ¥232,000+α | +39% |
| ¥3.7M~¥7.7M | ¥80,100+α | ¥113,000+α | +41% |
| ~¥3.7M | ¥57,600 | ¥60,000 | +4% |
| Tax-exempt | ¥35,400 | ¥35,400 | Unchanged |
A new ¥530,000 annual cap is introduced for those earning ¥2–7.7M/year, aimed at easing the burden on those needing long-term treatment. The multiple-occurrence reduction (cap reached 3+ times in the past 12 months) remains unchanged.
From June 2026, new price-adjustment surcharges effectively raise initial consultation by ~¥20 and follow-up by ~¥30. Affects out-of-pocket costs for foreign residents at 30% copay.
From April 2026, 34 more brand-name drugs added to the "selected medical treatment" list (total 775). Patients choosing brand-name over generic pay 1/4 of the price difference out of pocket. Affects foreign residents with chronic conditions.
From April 2026, drug prices cut by 0.86% (medical cost basis). Some items reduced by over 40% under market expansion reassessment. Lower out-of-pocket costs for foreign patients using prescription drugs.